Difference between revisions of "Fentanyl"
From WikiAnesthesia
Chris Rishel (talk | contribs) m (Added embedded dosage calculation) |
m |
||
Line 23: | Line 23: | ||
}} | }} | ||
'''Fentanyl''' is | '''Fentanyl''' is a synthetic, lipophilic phenylpiperidine opioid agonist used for analgesia. It is highly lipophilic leading to fast passage across the blood-brain barrier with a 6.8 minute onset time. Fentanyl will also rapidly redistribute to adipose and fatty tissue leading to a short duration of action. | ||
==Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. -->== | ==Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. -->== | ||
* Administration | |||
** IV, IM, transdermal, intranasal, intrathecal, epidural, buccal. | |||
==Contraindications<!-- List contraindications and precautions for use of the drug. -->== | ==Contraindications<!-- List contraindications and precautions for use of the drug. -->== | ||
Line 32: | Line 35: | ||
===Precautions<!-- List precautions for use of the drug. If none, this section may be removed. -->=== | ===Precautions<!-- List precautions for use of the drug. If none, this section may be removed. -->=== | ||
* | |||
==Pharmacology== | ==Pharmacology== | ||
Line 38: | Line 43: | ||
====Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. -->==== | ====Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. -->==== | ||
* µ-selective opioid receptor | |||
* Low affinity: delta & kappa opioid receptors | |||
====Adverse effects<!-- Describe any potential adverse effects of the drug. -->==== | ====Adverse effects<!-- Describe any potential adverse effects of the drug. -->==== | ||
===Pharmacokinetics<!-- Describe the pharmacokinetics of the drug. -->=== | ===Pharmacokinetics<!-- Describe the pharmacokinetics of the drug. -->=== | ||
* Context Sensitive Half Time | |||
** Infusion or repeated doses lead to prolong duration of action as drug redistributes back from tissue to plasma. | |||
==Chemistry and formulation<!-- Describe the chemistry and formulation of the drug. -->== | ==Chemistry and formulation<!-- Describe the chemistry and formulation of the drug. -->== | ||
Line 48: | Line 59: | ||
==References== | ==References== | ||
# Comer SD, Cahill CM. Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev. 2019 Nov;106:49-57. | |||
[[Category:Drug reference]] | [[Category:Drug reference]] |
Latest revision as of 18:31, 1 February 2023
Fentanyl
Trade names |
Actiq, Duragesic, Sublimaze |
---|---|
Clinical data | |
Drug class |
Opioid |
Uses |
Analgesia |
Routes of administration |
Buccal, Epidural, Intrathecal, Intravenous, Transdermal |
Dosage | |
Pharmacodynamics | |
Mechanism of action |
μ-opioid agonism |
Pharmacokinetics | |
Onset of action |
5 minutes |
Duration of action |
30-60 minutes |
Metabolism |
Hepatic (CYP3A4) |
Redistribution half-life |
6 minutes (initial) 1 hour (slow) |
Elimination half-life |
16 hours |
Protein binding |
80-85% |
Physical and chemical data | |
Formula |
5 minutes |
Molar mass |
336.479 g/mol |
Article quality | |
Editor rating | |
User likes | 0 |
Fentanyl is a synthetic, lipophilic phenylpiperidine opioid agonist used for analgesia. It is highly lipophilic leading to fast passage across the blood-brain barrier with a 6.8 minute onset time. Fentanyl will also rapidly redistribute to adipose and fatty tissue leading to a short duration of action.
Uses
- Administration
- IV, IM, transdermal, intranasal, intrathecal, epidural, buccal.
Contraindications
Absolute contraindications
Precautions
Pharmacology
Pharmacodynamics
Mechanism of action
- µ-selective opioid receptor
- Low affinity: delta & kappa opioid receptors
Adverse effects
Pharmacokinetics
- Context Sensitive Half Time
- Infusion or repeated doses lead to prolong duration of action as drug redistributes back from tissue to plasma.
Chemistry and formulation
History
References
- Comer SD, Cahill CM. Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev. 2019 Nov;106:49-57.
Top contributors: Chris Rishel and Jashvin Patel